Stock Financial Ratios


AKRX / Akorn, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price33.40
Volume1,090,400.00
Market Cap ($M)4,174.53
Enterprise Value ($M)4,662.57
Book Value ($M)819.18
Book Value / Share6.51
Price / Book4.70
NCAV ($M)2,847.67
NCAV / Share22.64
Price / NCAV2.23
Income Statement (mra) ($M)
Revenue1,116.84
EBITDA327.57
Net Income184.24
Balance Sheet (mrq) ($M)
Cash & Equivalents345.38
Cash / Share2.75
Assets2,044.75
Liabilities1,008.69
Quick Ratio2.91
Current Ratio3.91
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.11
Return on Assets (ROA)0.06
Return on Equity (ROE)0.22
Identifiers and Descriptors
CUSIP000972810
Central Index Key (CIK)3116
Industry Groups
SIC 2834 - Pharmaceutical Preparations
Other Related CUSIPS
009728AB2
009728956
009728906
009728106
Share Statistics
Common Shares Outstanding (M)125.07
Scoring Models
Piotroski F Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Accounts Receivable Per Share1.50
Inventory Work In Progress Per Share0.00
Additional Paid In Capital Per Share0.00
Inventory Finished Goods Per Share0.58
Property Plant And Equipment Per Share2.37
Treasury Stock Per Share0.00
Liabilities Other Non Current Per Share0.09
Goodwill Per Share2.26
Liabilities Per Share8.02
Deferred Income Tax Liabilities Per Share0.00
Accounts Payable Per Share0.44
Debt Per Share6.47
Inventory Per Share1.45
Cash And Equivalents Per Share2.75
Accumulated Depreciation And Depletion Per Share0.00
Intangibles Per Share5.54
Property Plant And Equipment Net Per Share2.37
Minority Interest Per Share0.00
Equity Per Share7.05
Current Portion Of Long Term Debt Per Share0.00
Property Plant And Equipment Gross Per Share0.00
Liabilities And Stock Equity Per Share16.33
Inventory Raw Materials Per Share0.00
Liabilities Current Per Share1.46
Assets Other Non Current Per Share0.02
Assets Other Current Per Share0.00
Retained Earnings Per Share2.86
Preferred Stock Value Outstanding Per Share0.00
Assets Non Current Per Share0.00
Long Term Debt Per Share6.47
Cash Per Share2.75
Assets Per Share16.25
Assets Current Per Share6.06

Related News Stories

Akorn/Fresenius: Risky Arb

2017-11-02 seekingalpha
The strategic value of the deal to Fresenius still makes sense, but Fresenius will be taking on some real and reputational risks. (19-0)

Insys Founder Charged in Bribe Scheme Linked to Fentanyl-Based Painkiller - The New York Times

2017-10-27 nytimes
The billionaire founder of Insys Therapeutics was arrested on Thursday on federal charges that he participated in a scheme to bribe doctors to prescribe a fentanyl-based painkiller intended for cancer patients. (19-0)

Allergan settles with one of four companies contesting Restasis patent

2017-10-12 reuters
(Reuters) - Allergan Plc said on Thursday it reached a settlement with InnoPharma Inc, one of the four generic drugmakers challenging the patents for its dry eye medication Restasis in federal court. (221-0)

Allergan Bulls Should Brace Themselves For Generic Restasis

2017-10-11 seekingalpha
Judge Bryson wants AGN to prove the Mohawks should be party to the federal patent litigation. (108-0)

Senvest Management shorting drug stocks Insys, Akorn, Fresenius

2017-10-03 reuters
TEL AVIV, Oct 3 (Reuters) - New York-based Senvest Management is shorting three drug stocks, Insys Therapeutics Inc , Akorn Inc and Fresenius SE, its chief executive Richard Mashaal said on Tuesday, (19-0)

CUSIP: 000972810